MBC that is positive for both hormone receptors (estrogen receptors/ER and progesterone receptors/PR) and HER2 is called triple positive. Approximately 10% of MBC is triple positive. Triple-positive MBC is different from hormone receptor-positive or HER2-positive MBC because triple-positive cancer is fueled by both hormone receptors and HER2. The interactions between HER2 and estrogen receptors may lead to resistance to hormone therapy or HER2 targeted therapy.
Read below for more information about triple-positive MBC, current thinking about treatment strategies, and results from a clinical trial testing first-line treatment.
- Very Well Health Triple-Positive Breast Cancer Overview
- OncLive Frontline Therapy for Triple-Positive Breast Cancer
- Journal article First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Triple-Positive MBC: The PERTAIN Trial
- Metastatic Trial Search Trials for people with triple-positive MBC
Last Modified on December 10, 2021